Drug intelligence / Profile preview

azd1704

Development stage: Phase 1
Lead developer: AstraZeneca
Modality: Small Molecules
Administration: Oral

Overview

AZD1704 is an investigational small molecule drug developed by AstraZeneca. It acts as an agonist at cannabinoid receptors CB1 and CB2. The compound was studied for its potential analgesic (pain-relieving) effects, with Phase 1 clinical trials conducted to assess its safety, tolerability, and pharmacokinetics in healthy volunteers. Despite initial development for pain management, the global highest R&D status of AZD1704 is discontinued. The drug was administered orally in clinical studies.

Targets

CNR1 (Cannabinoid receptor 1)

Beyond the preview

Go deeper on azd1704.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on azd1704.

Explore the full profile